Asunercept companion diagnostic - Apogenix/R Biopharm

Drug Profile

Asunercept companion diagnostic - Apogenix/R Biopharm

Alternative Names: APG101 companion diagnostic; Apocept™ companion diagnostic; Asinercept companion diagnostic; CD95-Fc fusion protein companion diagnostic

Latest Information Update: 25 Nov 2016

Price : $50

At a glance

  • Originator Apogenix; R-Biopharm
  • Developer Apogenix
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma
  • Clinical Phase Unknown Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 07 Oct 2016 Biomarker data from a phase II trial in Glioblastoma presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 16 Feb 2016 Apogenix receives other grant from German Federal Ministry of Education and Research for Asunercept companion diagnostic development
  • 28 Jul 2015 Apogenix and R Biopharm agree to co-develop companion diagnostic tests for asunercept in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top